Equities

Bio-Thera Solutions Ltd

688177:SHH

Bio-Thera Solutions Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)23.09
  • Today's Change-0.66 / -2.78%
  • Shares traded2.51m
  • 1 Year change-37.07%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bio-Thera Solutions, Ltd. is a China-based company mainly engaged in the research and development of innovative drugs and biosimilars. The Company is committed to the development of a new generation of antibody drugs to treat cancer, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life and health. The Company's main products include adalimumab BAT1406, bevacizumab BAT1706, BAT8001, tocilizumab BAT1806, batifaban BAT2094, BAT8003 and so on.

  • Revenue in CNY (TTM)825.18m
  • Net income in CNY-377.67m
  • Incorporated2003
  • Employees1.17k
  • Location
    Bio-Thera Solutions Ltd5F, Building A6, No.11 Kaiyuan Avenue, SGUANGZHOU 510530ChinaCHN
  • Phone+86 2 032203528
  • Fax+86 2 032203218
  • Websitehttps://www.bio-thera.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Beijing Sun-Novo Pharma Research Co Ltd1.16bn221.37m5.20bn1.39k23.504.60--4.501.981.9810.3310.100.607935.951.77844,377.1011.2512.9918.7621.7053.3053.9318.5021.341.8629.920.306810.7437.7647.2218.0854.9034.77--
Shanghai Medicilon Inc984.17m-276.79m5.45bn2.42k--2.32--5.54-2.01-2.017.2317.460.30296.901.27378,525.60-8.529.34-10.6611.730.644336.71-28.1214.932.64--0.114720.18-17.6833.26-109.82--23.60--
GemPharmatech Co Ltd677.34m139.41m5.88bn1.51k41.832.76--8.690.3430.3431.655.200.27034.542.06449,761.405.569.456.3911.1363.0470.2120.5828.164.74--0.050914.6820.4563.48-3.48--141.38--
HitGen Inc423.87m52.55m5.92bn452.00112.454.30--13.970.13140.13141.063.440.2487.104.55937,755.302.994.633.165.1051.2358.8912.0520.6616.1538.230.139119.1412.6419.6961.16-1.96-6.12--
InventisBio Co Ltd77.51m-348.02m6.26bn221.00--3.61--80.80-0.6064-0.60640.13463.010.0383--0.5855350,739.20-17.19---18.36--90.80---448.98------0.0138------41.26------
Bio-Thera Solutions Ltd825.18m-377.67m9.83bn1.17k--11.61--11.92-0.9121-0.91211.992.050.35331.006.83707,092.40-16.17-23.62-26.76-30.8169.8179.76-45.77-106.720.716-27.470.4531--54.86--17.87---3.78--
Mabwell Shanghai Bioscience Co Ltd169.42m-1.07bn9.99bn1.40k--5.21--58.97-2.69-2.690.4244.800.03790.0899.74113,628.50-24.10-37.61-30.74-45.9590.5081.54-636.41-2,112.261.25-41.980.5339--361.0327.88-10.28--17.35--
Joinn Laboratories China Co Ltd2.12bn-912.86k13.26bn2.59k--1.81--6.24-0.0064-0.00642.8210.680.21510.77147.32---0.098.99-0.10611.0731.8346.76-0.418432.012.851.250.008923.814.7842.20-63.0429.668.2123.46
InnoCare Pharma Ltd898.92m-375.51m13.35bn1.09k--3.46--14.85-0.2325-0.23250.5373.860.09221.323.73825,457.90-4.02---4.78--84.50---43.57--7.65--0.1547--18.09--28.80------
Data as of Nov 14 2024. Currency figures normalised to Bio-Thera Solutions Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

4.39%Per cent of shares held by top holders
HolderShares% Held
Penghua Fund Management Co., Ltd.as of 30 Jun 20244.21m1.03%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 20243.59m0.88%
China Southern Asset Management Co., Ltd.as of 30 Jun 20242.38m0.58%
GF Fund Management Co., Ltd.as of 30 Jun 20241.46m0.36%
Yinhua Fund Management Co., Ltd.as of 30 Jun 20241.43m0.35%
Bosera Asset Management Co., Ltd.as of 30 Jun 20241.27m0.31%
The Vanguard Group, Inc.as of 02 Oct 2024999.15k0.24%
China Universal Asset Management Co., Ltd.as of 30 Jun 2024973.73k0.24%
Chang Xin Asset Management Co., Ltd.as of 30 Jun 2024870.22k0.21%
China Asset Management Co., Ltd.as of 30 Jun 2024762.79k0.19%
More ▼
Data from 30 Jun 2024 - 29 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.